Analysts Set Abivax SA Sponsored ADR (NASDAQ:ABVX) Price Target at $128.73

Shares of Abivax SA Sponsored ADR (NASDAQ:ABVX) have been assigned a consensus recommendation of “Moderate Buy” from the thirteen brokerages that are currently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell rating, eleven have issued a buy rating and one has given a strong buy rating to the company. The average twelve-month target price among analysts that have issued a report on the stock in the last year is $128.7273.

Several equities research analysts recently weighed in on ABVX shares. BTIG Research lifted their target price on Abivax from $112.00 to $120.00 and gave the stock a “buy” rating in a research report on Monday, October 6th. Piper Sandler reiterated an “overweight” rating and issued a $142.00 price objective on shares of Abivax in a research report on Tuesday, December 16th. Guggenheim reissued a “buy” rating and set a $175.00 price objective on shares of Abivax in a report on Thursday, December 18th. Barclays began coverage on Abivax in a research note on Monday, October 13th. They issued an “overweight” rating and a $142.00 target price for the company. Finally, Wolfe Research upgraded shares of Abivax to a “strong-buy” rating in a research note on Thursday, November 6th.

Institutional Trading of Abivax

Institutional investors and hedge funds have recently added to or reduced their stakes in the business. UBS Group AG raised its position in Abivax by 2,561.0% in the third quarter. UBS Group AG now owns 4,461,262 shares of the company’s stock worth $378,761,000 after purchasing an additional 4,293,606 shares in the last quarter. Darwin Global Management Ltd. acquired a new position in shares of Abivax in the 3rd quarter worth approximately $263,698,000. Paradigm Biocapital Advisors LP acquired a new position in shares of Abivax in the 3rd quarter worth approximately $132,800,000. Octagon Capital Advisors LP bought a new position in shares of Abivax during the 1st quarter worth approximately $7,688,000. Finally, TCG Crossover Management LLC boosted its stake in Abivax by 17.4% in the 3rd quarter. TCG Crossover Management LLC now owns 7,111,596 shares of the company’s stock valued at $603,774,000 after buying an additional 1,055,000 shares in the last quarter. Institutional investors own 47.91% of the company’s stock.

Abivax Trading Up 7.1%

Shares of ABVX stock opened at $148.12 on Friday. The firm has a market capitalization of $11.54 billion, a P/E ratio of -85.62 and a beta of 0.48. Abivax has a 1 year low of $4.77 and a 1 year high of $148.83. The firm’s fifty day simple moving average is $111.45 and its 200 day simple moving average is $74.67. The company has a current ratio of 7.86, a quick ratio of 7.86 and a debt-to-equity ratio of 0.03.

Abivax (NASDAQ:ABVX) last issued its quarterly earnings results on Monday, December 15th. The company reported ($2.46) earnings per share for the quarter. The business had revenue of ($4.92) million for the quarter. As a group, sell-side analysts predict that Abivax will post -2.83 EPS for the current year.

About Abivax

Founded in 2013 and headquartered in Paris, France, Abivax is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for chronic inflammatory diseases and viral infections. The company’s technology platform targets host RNA biogenesis to modulate key immune pathways, offering a differentiated approach aimed at disease modification and improved safety profiles.

Abivax’s lead clinical asset, obefazimod (ABX464), is being evaluated in ulcerative colitis and other inflammatory disorders.